An immunotherapy from the drug firms Regeneron and Sanofi extended survival in previously untreated patients with non-small cell lung cancer, the companies said Monday.
Only one other such medicine, Merck’s Keytruda, has had a similar benefit in a similar population, said George D. Yancopoulos, Regeneron’s co-founder and chief scientific officer. He hopes, he said, that the Regeneron-Sanofi drug, called Libtayo, can provide an “alternative” to Keytruda in first-line non-small cell lung cancer.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
